Furfine ES - Search Results

1

Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.

Miller JF, Brieger M, Furfine ES, Hazen RJ, Kaldor I, Reynolds D, Sherrill RG, Spaltenstein A. Miller JF, et al. Among authors: furfine es. Bioorg Med Chem Lett. 2005 Aug 1;15(15):3496-500. doi: 10.1016/j.bmcl.2005.05.129. Bioorg Med Chem Lett. 2005. PMID: 15990305

2

In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

Hazen R, Harvey R, Ferris R, Craig C, Yates P, Griffin P, Miller J, Kaldor I, Ray J, Samano V, Furfine E, Spaltenstein A, Hale M, Tung R, St Clair M, Hanlon M, Boone L. Hazen R, et al. Antimicrob Agents Chemother. 2007 Sep;51(9):3147-54. doi: 10.1128/AAC.00401-07. Epub 2007 Jul 9. Antimicrob Agents Chemother. 2007. PMID: 17620375 Free PMC article.

3

Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease.

Kazmierski WM, Furfine E, Spaltenstein A, Wright LL. Kazmierski WM, et al. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3431-3. doi: 10.1016/s0960-894x(02)00733-3. Bioorg Med Chem Lett. 2002. PMID: 12419377

4

Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O-->N acyloxy migration of P1 moiety.

Kazmierski WM, Bevans P, Furfine E, Spaltenstein A, Yang H. Kazmierski WM, et al. Bioorg Med Chem Lett. 2003 Aug 4;13(15):2523-6. doi: 10.1016/s0960-894x(03)00463-3. Bioorg Med Chem Lett. 2003. PMID: 12852957

5

Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.

Kazmierski WM, Furfine E, Gray-Nunez Y, Spaltenstein A, Wright L. Kazmierski WM, et al. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5685-7. doi: 10.1016/j.bmcl.2004.08.038. Bioorg Med Chem Lett. 2004. PMID: 15482948

6

Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.

Kazmierski WM, Andrews W, Furfine E, Spaltenstein A, Wright L. Kazmierski WM, et al. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5689-92. doi: 10.1016/j.bmcl.2004.08.039. Bioorg Med Chem Lett. 2004. PMID: 15482949

7

New, potent P1/P2-morpholinone-based HIV-protease inhibitors.

Kazmierski WM, Furfine E, Spaltenstein A, Wright LL. Kazmierski WM, et al. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5226-30. doi: 10.1016/j.bmcl.2006.07.014. Epub 2006 Aug 10. Bioorg Med Chem Lett. 2006. PMID: 16904316

8

Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.

Miller JF, Furfine ES, Hanlon MH, Hazen RJ, Ray JA, Robinson L, Samano V, Spaltenstein A. Miller JF, et al. Among authors: furfine es. Bioorg Med Chem Lett. 2004 Feb 23;14(4):959-63. doi: 10.1016/j.bmcl.2003.12.008. Bioorg Med Chem Lett. 2004. PMID: 15013001

9

Optimization of pyrrolidinone based HIV protease inhibitors.

Sherrill RG, Andrews CW, Bock WJ, Davis-Ward RG, Furfine ES, Hazen RJ, Rutkowske RD, Spaltenstein A, Wright LL. Sherrill RG, et al. Among authors: furfine es. Bioorg Med Chem Lett. 2005 Jan 3;15(1):81-4. doi: 10.1016/j.bmcl.2004.10.029. Bioorg Med Chem Lett. 2005. PMID: 15582415

10

Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.

Sherrill RG, Furfine ES, Hazen RJ, Miller JF, Reynolds DJ, Sammond DM, Spaltenstein A, Wheelan P, Wright LL. Sherrill RG, et al. Among authors: furfine es. Bioorg Med Chem Lett. 2005 Aug 1;15(15):3560-4. doi: 10.1016/j.bmcl.2005.05.101. Bioorg Med Chem Lett. 2005. PMID: 15975788

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters